Overview

Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Status:
Recruiting

Trial end date:
2023-01-20

Target enrollment:

Participant gender:

Summary

In this single-arm study, pathologically confirmed advanced head and neck squamous cell carcinoma will be enrolled to investigate the efficacy and safety of Camrelizumab in combination With albumin paclitaxel and cisplatin.

Phase:

Phase 2

Details

Lead Sponsor:

Hunan Cancer Hospital

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Cisplatin
Immune Checkpoint Inhibitors
Paclitaxel